A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Completed · Phase 1

Conditions studied: Cancer

In brief

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the study is to determine the safety, tolerability, and RP2D of BBI503 in combination with each of the selected anti-cancer agents.

Key facts

Study ID

NCT02483247

Run by

Sumitomo Pharma America, Inc.

People needed

165

Starts

2015-09-01

Expected to finish

2019-05-01

Last updated by the study team

2023-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Parkview Research Center — Fort Wayne, Indiana, United States
• Indiana University Health Goshen — Goshen, Indiana, United States
• Indiana University -Ball — Indianapolis, Indiana, United States
• Indiana University-SCC — Indianapolis, Indiana, United States
• Louisiana State Univesity — New Orleans, Louisiana, United States
• US Oncology Research — Fairfax, Virginia, United States
• Ottawa Hospital Research Institute — Ottawa, Ontario, Canada
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.